We remain committed to bringing an ophthalmic bevacizumab to market in the United States and providing retina patients suffering from wet AMD with a much needed treatment option that has the potential ...

Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...

Outlook Therapeutics (OTLK) announced it has re-submitted its Biologics License Application, BLA, to the U.S. Food and Drug Administration, ...

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) had its price target reduced by research analysts at Ascendiant Capital Markets from $33.00 to $24.00 in a research note issued to investors on ...

On-demand video webcast now available here ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval ...

Fintel reports that on February 28, 2025, JP Morgan downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...

Fintel reports that on February 27, 2025, HC Wainwright & Co. downgraded their outlook for LAVA Therapeutics N.V.

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing novel therapies for hematopoietic stem cell transplantation and mast cell-mediated diseases.

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, has been making significant strides in the ...